On the evening of January 27, Lanzhou Foci Pharmaceutical Co.Ltd(002644) announced that the controlling shareholder foci group plans to introduce strategic investors through the mixed reform, which may lead to the change of the actual controller of the company.
The news that the controlling shareholder intends to introduce war investment has been recognized by the market. After the opening of Lanzhou Foci Pharmaceutical Co.Ltd(002644) today, it rose the limit word by word until the closing.
the mixed reform plans to introduce Central Pharmaceutical Enterprises
Specifically, in order to implement the three-year action plan for the reform of state-owned enterprises in Lanzhou (2020-2022), foci group plans to introduce war investment through mixed reform, which has been approved by Lanzhou SASAC.
According to the third quarterly report of Lanzhou Foci Pharmaceutical Co.Ltd(002644) 2021, foci group holds Lanzhou Foci Pharmaceutical Co.Ltd(002644) about 315 million shares, accounting for 61.63% of the total share capital. It is the controlling shareholder of the company, and the actual controller of the company is Lanzhou SASAC.
According to people familiar with the matter, Lanzhou SASAC should make a great determination on the mixed reform of foci group.
Up to now, Lanzhou SASAC has only Lanzhou Foci Pharmaceutical Co.Ltd(002644) one A-share company’s actual control. If it “cedes” the company’s control through mixed reform, it will no longer control the platform of A-share listed companies.
” Lanzhou Foci Pharmaceutical Co.Ltd(002644) has been exploring the mixed reform.” An insider close to Lanzhou SASAC told reporters that based on the recognition of foci brand and products, China Fangda Group Co.Ltd(000055) and Fosun Group had previously discussed equity level cooperation with Lanzhou Foci Pharmaceutical Co.Ltd(002644) .
The reporter noted that although it failed to “strike” sparks with Fang Da and Fosun, from the perspective of the “qualifications” of potential partners in the past, the war investment proposed to be introduced by foci group should be “of great origin”.
Who is the war investment to be introduced by foci group in this mixed reform? The above-mentioned person disclosed to reporters that the partner is a central pharmaceutical enterprise, and the cooperation scheme is currently under discussion.
For the mixed reform at the level of controlling shareholders, Lanzhou Foci Pharmaceutical Co.Ltd(002644) said that the plan of introducing strategic investors by foci group is in the planning stage, the start-up time has not been determined, and the plan also needs to be approved by the relevant competent authorities, but it has no impact on the production and operation of the company.
improving the vitality of “time-honored brands” through mixed reform
It has been 92 years since the first concentrated pill of traditional Chinese medicine was created to have 467 drug production approval numbers. The time-honored brand “foci” was founded in 1929.
As one of the “leaders in the industrialization of traditional Chinese medicine”, Lanzhou Foci Pharmaceutical Co.Ltd(002644) has been widely recognized by the market for its genuine material selection, excellent technology and accurate curative effect. “Foci” brand has also become one of the first batch of “Chinese time-honored brands” recognized by the Ministry of Commerce.
The company’s products have a good influence in the traditional Chinese medicine industry. It is understood that in addition to the perennial production of more than 110 products in 11 dosage forms such as concentrated pills and big honey pills, the company also has 10 national exclusive products such as Shenrong gubenhuanshao pills, Dingxuan pills, bamboo leaf pepper tablets, Eryi pills and Compound Huangqi Jianpi oral liquid.
In terms of medical insurance products, a total of 215 products of the company have entered the 2019 national medical insurance catalogue. Among them, the exclusive variety Shugan Xiaoji pill and the characteristic product Jisheng Juhe pill have entered the category B scope of the medical insurance catalogue.
It is worth mentioning that the company’s products, Qihuang BiWen Decoction and Xuanfei Huazhuo decoction, were selected into the prevention and treatment Decoction of covid-19 pneumonia prevention formula of traditional Chinese medicine in Gansu Province (2021 Edition). Among them, the preventive prescription Qihuang BiWen decoction is suitable for people who are susceptible to physical deficiency; The therapeutic prescription Xuanfei Huazhuo decoction is suitable for the treatment of mild patients and the prevention of close contact people.
“Foci has deep foundation and development potential in the field of traditional Chinese medicine.” A relevant person familiar with Gansu Capital Market told reporters that the market scale of foci products still has a lot of room to improve, and the entry of the central enterprise pharmaceutical platform is expected to further enhance the brand vitality of time-honored brands.
